We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
2403
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
• DirectRx, a specialty pharmacy, will distribute Ohtuvayre (ensifentrine), a new FDA-approved inhaled maintenance therapy for chronic obstructive pulmonary disease (COPD). • Ohtuvayre, developed by Verona Pharma, is priced at $2,950 per month and represents the first new COPD therapy mechanism in over two decades. • Clinical trials (ENHANCE-1 and ENHANCE-2) demonstrated that Ohtuvayre significantly improved lung function and reduced exacerbation rates in COPD patients. • Ohtuvayre's active component, ensifentrine, inhibits phosphodiesterase 3 and 4, reducing inflammation and widening airways, offering a novel approach to COPD management.
